OakChart

MiNK Therapeutics Inc

INKTHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 11:01 AM ET

10.45+0.44 (4.40%)
2026-11-11 17:01 CET
Market cap
51.08 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-11.36 USD m
Free cash flow, TTM
-6.83 USD m
EPS diluted, TTM
-2.40
P/E
-
Compare

Price

INKT against its 20, 50 and 200-day averages
2050200earnings
9.0010.0011.0012.0013.00109K217KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INKTclose 10.4520-day 10.3550-day 11.18200-day 11.2210.45

38.3% under the 52-week high of 16.93 on 10 Mar 2026. 52-week low 8.48 on 24 Mar 2026. Last 15 sessions, 21.6% high to low

Profile

INKT
52-week range, 23% of the way up
8.4816.93

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded by Garo H. Armen in 2017 and is headquartered in New York, NY.

Employees15
IPOOct 15, 2021
Beta0.45
ATR, 14d0.73
Rel volume1.30
Short float2.70%
Insider own60.10%
Inst own4.06%

Snapshot

6 groups

Valuation

Index-
Market Cap53.33M
Enterprise Value44.52M
Income-11.36M
Sales0.00M
Book/sh-2.75
Cash/sh1.73
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees15
IPOOct 15, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C6.05
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.23
Current Ratio1.23
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.40
EPS next Y-1.56
EPS next Q-0.51
EPS this Y13.65%
EPS next Y38.14%
EPS next 5Y20.18%
EPS past 3/5Y29.40% 9.83%
Sales past 3/5Y- -
EPS Y/Y TTM15.65%
Sales Y/Y TTM-
EPS Q/Q41.49%
Sales Q/Q-
EarningsNov 11 BMO
EPS/Sales Surpr.24.24% 0.00%

Ownership

Insider Own60.10%
Insider Trans-0.27%
Inst Own4.06%
Inst Trans8.46%
ROA-187.78%
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.96%
SMA50-6.50%
SMA200-6.84%
Trades-

Technical

Shs Outstand5.10M
Shs Float2.04M
Short Float2.70%
Short Ratio3.89
Short Interest0.06M
52W High16.93 -38.26%
52W Low8.48 23.23%
Volatility7.46% 7.15%
ATR (14)0.73
RSI (14)47.56
Beta0.45
Rel Volume1.30
Avg Volume14.16K
Volume5,019

Performance

Perf Week-1.42%
Perf Month2.15%
Perf Quarter-5.00%
Perf Half Y-5.43%
Perf YTD-6.28%
Perf Year-23.50%
Perf 3Y-0.48%
Perf 5Y-94.78%
Perf 10Y-
Recom1.00
Target Price43.55
Prev Close10.01
Price10.45
Change %4.40%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Nov 04, 2026ResumedHH.C. WainwrightBuy$38+263.6%
Aug 15, 2025UpgradeHH.C. WainwrightNeutral → Buy$35+234.9%
Jul 14, 2025DowngradeWWilliam BlairOutperform → Mkt Perform

Peers

Mkt cap
TickerCompanyMkt cap
NKTXNkarta Inc97.16M
FATEFate Therapeutics Inc204.85M
ACETAdicet Bio Inc28.69M
IPSCCentury Therapeutics Inc310.35M
AGENAgenus Inc321.02M
ALLOAllogene Therapeutics Inc308.94M
CELUCelularity Inc22.75M
CRBUCaribou Biosciences Inc41.06M
ATRAAtara Biotherapeutics Inc83.72M
IBRXImmunityBio Inc7.06B

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Buell JenniferChief Executive OfficerOct 12 '26Sale10.566,93873,26574,195Oct 14 02:36 PM
Buell JenniferOfficerOct 12 '26Proposed Sale10.566,93873,275Oct 13 08:36 AM
Ryan BarbaraDirectorJun 04 '26Sale12.761,50019,14121,969Jun 05 06:04 PM
Ryan BarbaraDirectorMar 10 '26Sale15.401,30020,01720,406Mar 11 06:22 PM
Ryan BarbaraDirectorMar 09 '26Sale10.172002,03421,706Mar 11 06:22 PM
Ryan BarbaraDirectorFeb 27 '26Sale10.864004,34322,006Mar 04 04:45 PM
Ryan BarbaraDirectorMar 02 '26Sale10.831001,08321,906Mar 04 04:45 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 103
  • MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies (GlobeNewswire)
  • MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) (GlobeNewswire)
  • MiNK Therapeutics Faces First Test Of Paid Access Revenue As Cash Cushion Thins (Earnings Whispers)
  • MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy (GlobeNewswire)
  • MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 (GlobeNewswire)
  • Loading…
  • MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy (GlobeNewswire)
  • MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ... (GuruFocus.com)
  • MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury (GlobeNewswire)
  • MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium (GlobeNewswire) -5.98%
  • MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates (GlobeNewswire)
  • Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer (Business Wire)
  • MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting (GlobeNewswire) +6.69%
  • MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness (GlobeNewswire) +19.84%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-11-0.500-0.660-1.0600.080.082
2026Q22026-08-13-0.620-0.600-1.0600.000.001
2026Q12026-05-15-0.570-0.770-0.5720.000.001
2025Q42026-03-31-0.520-0.680-0.5530.000.001
2025Q32025-11-14-0.650-0.855-0.6500.000.002
2025Q22025-08-14-1.060-0.547-1.0640.000.003
2025Q12025-05-15-0.700-0.608-0.6980.000.002
2024Q42025-03-18-0.620-0.487-0.6230.000.003
2024Q32024-11-14-0.500-0.801-0.4570.000.003
2024Q22024-08-13-0.700-0.982-0.7270.000.003
2024Q12024-05-14-1.100-1.525-1.1010.000.003
2023Q42024-03-21-1.600-1.525-1.5800.000.003
2023Q32023-11-09-1.500-1.816-1.4830.000.004
2023Q22023-08-10-1.800-1.975-1.8010.000.004
2023Q12023-05-11-1.700-2.379-1.6740.000.004
2022Q42023-03-21-2.300-2.097-2.2980.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-11.600-8.000-9.0250.00-
2022FY-8.300-8.301-8.3130.000.00
2023FY-6.500-6.510-6.5360.000.00
2024FY-2.860-3.647-2.8580.000.00
2025FY-2.930-3.070-6.6000.000.00
2026FY--2.530--0.20
2027FY--1.565--0.75
2028FY--1.490--7.50
2029FY--2.850--16.65
2030FY--0.730--54.29

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-032010.080.000.15
2026Q3S2026-10-272000.880.151.60
2026Q3S2026-10-202100.880.151.60
2026Q3S2026-08-131101.601.601.60
2026Q3S2026-05-151000.000.000.00
2026Q3S2026-03-311000.000.000.00
2026Q3S2025-11-141000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00

Estimate history

EPS, annual-7.194-4.908-9.025-8.313-6.536-2.858-2.926-2.3971
Period2019202020212022202320242025TTM
EPS, quarterly-0.727-0.457-0.623-0.698-1.064-0.65-0.553-0.572-0.623
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.690000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual3.3093.3093.3483.3863.463.9634.7065.097
Period2019202020212022202320242025MRQ
Shares, quarterly3.9453.9553.9633.9663.994.6014.7064.9695.097
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.69
Cost of Goods Sold Incl. D&A0.150.180.220.200.120.080.06-
Gross Profit-0.15-0.18-0.22-0.20-0.12-0.08-0.06-
Selling, General and Administrative Excl. Other12.2112.3110.4322.7230.8318.5310.7423.45
Research and Development5.755.766.3415.4923.1213.979.5119.65
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.36-12.49-10.65-22.92-30.95-18.61-10.80-22.79
Interest Expense---0.000.002.432.441.56
Unusual Expense-0.380.150.45-0.270.009.403.84-0.51
Net Income Before Taxes-11.36-12.49-10.78-22.46-27.99-30.21-16.24-23.80
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-11.36-12.49-10.78-22.46-27.99-30.21-16.24-23.80
Net Income From Continuing Operations-11.36-12.49-10.78-22.46-27.99-30.21-16.24-23.80
Net Income-11.36-12.49-10.78-22.46-27.99-30.21-16.24-23.80
EPS (Recurring)-2.31-2.90-2.77-6.59-8.31-7.06-4.10-7.30
EPS (Basic, Before Extraordinaries)-2.40-2.93-2.86-6.54-8.31-9.03-4.91-7.19
EPS (Diluted)-2.40-2.93-2.86-6.54-8.31-9.03-4.91-7.19
EBITDA-12.21-12.31-10.43-22.72-30.83-18.53-10.74-22.76
Non-Operating Income (Expense)0.630.150.320.202.960.220.840.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.682.102.843.833.031.750.090.22
Operating Margin--------3,305.06
Net Margin--------3,451.46
Shares Outstanding5.104.713.963.463.393.353.313.31
Market Capitalization51.0851.0827.6236.9488.18149.31100.99-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.040.040.040.040.050.050.050.06
Gross Profit-0.04-0.04-0.04-0.04-0.05-0.05-0.05-0.06
Selling, General and Administrative Excl. Other3.182.853.242.953.642.482.161.64
Research and Development1.891.201.511.141.841.261.410.54
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.22-2.88-3.28-2.99-3.69-2.53-2.21-1.70
Unusual Expense0.000.00-0.570.190.360.170.290.18
Net Income Before Taxes-3.13-2.74-2.60-2.89-4.24-2.77-2.46-1.81
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.13-2.74-2.60-2.89-4.24-2.77-2.46-1.81
Net Income From Continuing Operations-3.13-2.74-2.60-2.89-4.24-2.77-2.46-1.81
Net Income-3.13-2.74-2.60-2.89-4.24-2.77-2.46-1.81
EPS (Recurring)-0.62-0.57-0.64-0.62-1.00-0.67-0.57-0.42
EPS (Basic, Before Extraordinaries)-0.62-0.57-0.55-0.65-1.06-0.70-0.62-0.46
EPS (Diluted)-0.62-0.57-0.55-0.65-1.06-0.70-0.62-0.46
EBITDA-3.18-2.85-3.24-2.95-3.64-2.48-2.16-1.64
Non-Operating Income (Expense)0.090.140.100.30-0.19-0.070.040.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.420.630.010.620.900.570.390.88
Shares Outstanding5.104.974.714.603.993.973.963.95
Market Capitalization51.0849.4352.3463.3229.4434.2727.6229.66

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments13.364.583.3719.6438.892.690.30
Short Term Receivables0.000.000.000.000.020.250.53
Inventories0.000.000.000.000.000.000.00
Other Current Assets0.490.410.230.770.720.610.09
Total Current Assets13.854.993.6020.4039.633.560.92
Net Property, Plant & Equipment0.390.730.951.070.610.460.39
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.540.00
Total Assets14.245.724.5521.4740.244.561.31
Short Term Debt Incl. Current Port. of LT Debt5.180.000.000.000.000.000.00
Accounts Payable3.432.733.915.823.003.142.46
Other Current Liabilities4.434.237.496.8613.4711.084.96
Total Current Liabilities13.036.9611.4012.6816.4714.227.42
Long Term Debt0.004.920.000.000.0043.8226.79
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities15.4413.4211.219.190.000.383.43
Total Liabilities28.4725.3122.6121.8716.4758.4337.64
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity-14.23-19.59-18.06-0.4023.78-53.87-36.33
Total Shareholders Equity-14.23-19.59-18.06-0.4023.78-53.87-36.33
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity-14.23-19.59-18.06-0.4023.78-53.87-36.33
Total Liabilities & Stockholders Equity14.245.724.5521.4740.244.561.31
Book Value Per Share-3.02-4.94-5.22-0.127.10-16.28-10.98
Tangible Book Value Per Share-3.02-4.94-5.22-0.127.10-16.28-10.98
Full-Time Employees152331373327-
Price to Book Ratio-3.64-1.41-2.7213.056.28-1.32-
Return on Assets-125.20-209.96-172.59-90.71-134.89-553.84-
Return on Equity----239.50---
Return on Invested Capital-----127.07--
Quick Ratio1.060.720.321.612.410.250.12
Current Ratio1.060.720.321.612.410.250.12

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-11.36-12.49-10.78-22.46-27.99-30.21-16.24-23.80
Depreciation0.150.180.220.200.120.080.060.04
Other Funds (Non Cash)1.913.100.553.590.2413.576.371.27
Funds from Operations-9.29-9.21-10.02-18.66-27.63-16.56-9.81-22.49
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital2.463.290.462.908.773.741.487.55
Cash from Operating Activities-6.83-5.93-9.56-15.76-18.87-12.83-8.34-14.94
Capital Expenditures0.000.000.00-0.07-0.25-0.25-0.10-0.43
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.07-0.25-0.25-0.10-0.43
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock19.4114.905.820.070.0039.800.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock19.4114.905.820.070.0039.800.000.00
Proceedsfrom Stock Options18.8414.455.800.000.0039.800.000.00
Issuance or Reduction of Debt, Net-5.000.005.000.000.009.4611.1111.44
Change in Long Term Debt-5.000.005.000.000.009.4611.1111.44
Issuance of Long Term Debt0.000.005.000.000.009.4611.1111.44
Reduction of Long Term Debt-5.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.43-0.170.00-0.48-0.160.000.000.00
Other Financing Activities Uses-0.43-0.170.00-0.48-0.160.000.000.00
Cash from Financing Activities13.9914.7210.82-0.41-0.1649.2611.1111.44
Exchange Rate Effect-0.03-0.01-0.05-0.030.020.02-0.28-0.12
Net Change in Cash7.138.781.21-16.27-19.2536.202.39-4.06
Free Cash Flow-6.83-5.93-9.56-15.84-19.12-13.08-8.43-15.37
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments8.819.5313.3614.281.683.23
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.490.500.490.250.330.34
Total Current Assets9.3010.0213.8514.532.013.58
Net Property, Plant & Equipment0.320.350.390.430.470.69
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets9.6210.3814.2414.962.484.27
Short Term Debt Incl. Current Port. of LT Debt0.000.005.185.735.515.12
Accounts Payable3.923.393.433.693.312.66
Other Current Liabilities3.653.904.434.024.344.34
Total Current Liabilities7.577.2913.0313.4313.1612.12
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities16.0715.7815.4415.0414.5113.94
Total Liabilities23.6423.0628.4728.4827.6726.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-14.03-12.69-14.23-13.51-25.19-21.79
Total Shareholders Equity-14.03-12.69-14.23-13.51-25.19-21.79
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-14.03-12.69-14.23-13.51-25.19-21.79
Total Liabilities & Stockholders Equity9.6210.3814.2414.962.484.27
Book Value Per Share-2.75-2.55-3.02-2.94-6.31-5.50
Tangible Book Value Per Share-2.75-2.55-3.02-2.94-6.31-5.50
Full-Time Employees--15---
Price to Book Ratio-3.64-3.48-3.80-2.22-1.34-1.75
Return on Assets-187.78-170.30-125.20-110.63-176.06-174.52
Quick Ratio1.231.381.061.080.150.30
Current Ratio1.231.381.061.080.150.30

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.13-2.74-2.60-2.89-4.24-2.77
Depreciation0.040.040.040.040.050.05
Other Funds (Non Cash)0.420.630.020.841.450.78
Funds from Operations-2.67-2.08-2.54-2.00-2.74-1.93
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.590.340.471.061.170.59
Cash from Operating Activities-2.08-1.73-2.07-0.94-1.57-1.34
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.373.151.3513.550.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.373.151.3513.550.000.00
Proceedsfrom Stock Options1.373.021.3213.140.000.00
Issuance or Reduction of Debt, Net0.00-5.000.000.000.000.00
Change in Long Term Debt0.00-5.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.00-5.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.25-0.170.000.000.00
Other Financing Activities Uses0.00-0.25-0.170.000.000.00
Cash from Financing Activities1.37-2.101.1813.550.000.00
Exchange Rate Effect-0.00-0.00-0.02-0.010.02-0.00
Net Change in Cash-0.72-3.83-0.9212.60-1.55-1.34
Free Cash Flow-2.08-1.73-2.07-0.94-1.57-1.34

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.70%0.1M2.0M14.16K
2026-10-152.34%0.0M2.0M13.77K
2026-09-302.42%0.0M2.1M12.81K
2026-09-152.79%0.1M2.1M13.16K
2026-08-313.28%0.1M2.0M17.46K
2026-08-143.94%0.1M2.0M24.32K
2026-07-314.85%0.1M1.9M27.21K
2026-07-155.13%0.1M1.9M35.78K
2026-06-305.80%0.1M1.9M42.49K
2026-06-155.97%0.1M1.9M52.35K
2026-05-296.03%0.1M1.9M308.92K
2026-05-156.37%0.1M1.9M301.91K
2026-04-305.55%0.1M1.8M303.20K
2026-04-155.51%0.1M1.8M299.90K
2026-03-317.95%0.1M1.8M292.97K
2026-03-139.07%0.1M1.7M281.78K
2026-02-272.25%0.0M1.7M13.19K
2026-02-131.90%0.0M1.7M15.52K
2026-01-302.03%0.0M1.7M17.73K
2026-01-151.93%0.0M1.7M19.00K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-144Statement of changes in beneficial ownership of securities2026-10-11SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-06-238-KCurrent report2026-06-17SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-17SEC
2026-04-304Statement of changes in beneficial ownership of securities2025-09-23SEC
2026-04-093Initial statement of beneficial ownership of securities2026-03-13SEC
2026-03-3110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-318-KCurrent report2026-03-31SEC
2026-03-278-KCurrent report2026-03-27SEC
2026-03-233Initial statement of beneficial ownership of securities2026-03-13SEC
2026-03-198-KCurrent report2026-03-13SEC
2026-03-114Statement of changes in beneficial ownership of securities2026-03-09SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-02-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100073.27K1
2026-090000
2026-080000
2026-070000
2026-060019.14K1
2026-050000
2026-040000
2026-030023.13K3
2026-02004.34K1
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC1.38%
DnB Asset Management AS1.11%
GEODE CAPITAL MANAGEMENT, LLC0.37%
Longbow Finance SA0.33%
CITADEL ADVISORS LLC0.31%
BlackRock, Inc.0.27%
VANGUARD FIDUCIARY TRUST CO0.17%
Steward Partners Investment Advisory, LLC0.04%
US BANCORP \DE\0.04%
UBS Group AG0.03%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.07%
VANGUARD EXTENDED MARKET INDEX FUND0.31%
iShares Micro-Cap ETF0.14%
Fidelity Extended Market Index Fund0.13%
Fidelity Series Total Market Index Fund0.06%
Fidelity Total Market Index Fund0.04%
Fidelity Nasdaq Composite Index Fund0.03%
1290 VT Micro Cap Portfolio0.01%
VANGUARD BALANCED INDEX FUND0.00%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. INKT. Cached 15 minutes.